Latest Healthcare It News

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.

Hydrix Limited reports back-to-back profitable quarters driven by strong margins and cost efficiencies, underpinned by a robust $40 million sales opportunity pipeline in cardiac and medtech sectors.

CurveBeam AI has broadened its commercial agreement with Stryker to cover Australia and New Zealand, aiming to accelerate adoption of its HiRise weight bearing CT scanners through targeted surgeon education and promotion.

EBR Systems has signed a long-term lease for a 51,000 sq ft facility in Santa Clara, California, positioning itself for significant manufacturing expansion and future growth in wireless cardiac pacing technology.

Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.

ECS Botanics reports a striking 339% quarter-on-quarter growth in its B2C sales, offsetting a slight dip in total revenue as it pivots to a hybrid B2B and B2C business model. The company’s record harvest and new product launches position it for a promising turnaround.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.

AMCIL Limited posted a half-year profit of $3.6 million, down 12.6%, yet its portfolio outperformed the S&P/ASX 200 with an 8.7% return. The company declared a steady interim dividend amid cautious market conditions.